Business Description

Agios Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company based in Cambridge, Massachusetts. The company focuses on discovering and developing innovative therapies for rare, genetically defined metabolic diseases, particularly in the field of classical hematology. Its lead product, mitapivat (marketed as PYRUKYND and AQVESME), is an approved oral therapy for adults with pyruvate kinase (PK) deficiency and thalassemia.

Everything on Agios Pharmaceuticals, Inc.

Revenue (FY2025) $54M
YoY growth +48.0%
Operating margin -873.9%
Direction Expanding
Gross margin 88.3%
Net margin -764.0%

Earnings Transcripts

View all transcripts ↗

Leadership & board

View leadership ↗
Brian Goff — Chief Executive Officer and Director View full profile ↗ Cecilia Jones — Chief Financial Officer View full profile ↗ James Burns — Chief Legal Officer View full profile ↗ Sarah Gheuens — Chief Medical Officer, Head of Research & Development View full profile ↗ Tsveta Milanova — Chief Commercial Officer View full profile ↗ Krishnan Viswanadhan — Chief Corporate Development & Strategy Officer View full profile ↗ Jacqualyn Fouse — Chair of the Board View full profile ↗ Rahul Ballal — Director View full profile ↗ Cynthia Smith — Director View full profile ↗ Kaye Foster — Director View full profile ↗ Maykin Ho — Director View full profile ↗ Jeffrey Capello — Director View full profile ↗ Catherine Owen Adams — Director View full profile ↗ David Scadden — Director View full profile ↗ Jay Backstrom — Director View full profile ↗

Share Repurchase Program

Latest FY repurchased
$0

Named Competitors

BioMarin PharmaceuticalBristol-Myers SquibbCellarityCRISPR TherapeuticsDISC MedicineEmmaus Life SciencesFulcrum TherapeuticsGeronHalia TherapeuticsIncyteIonis PharmaceuticalsItalfarmacoMaze TherapeuticsMerckNGGTNovartisNovo NordiskOtsuka PharmaceuticalPfizerPharmaEssentiaProtagonist TherapeuticsPTC TherapeuticsSanofiSilence TherapeuticsTakedaVertex Pharmaceuticals +14 more

Customer Concentration

One customer accounted for 89% of Agios's consolidated revenue for the year ended December 31, 2025 (95% in 2024 and 96% in 2023), reflecting distribution of PYRUKYND through a concentrated specialty-pharmacy/distributor channel.

Recent SEC Filings

2026-07-30 Reported quarterly results View filing ↗
2026-06-18 Leadership change (directors/officers) (+1 more) View filing ↗
2026-04-29 Reported quarterly results View filing ↗
2026-02-12 Reported quarterly results View filing ↗
2026-01-12 Regulation FD disclosure View filing ↗
2025-10-30 Reported quarterly results View filing ↗
2025-08-04 Regulation FD disclosure View filing ↗
2025-07-31 Reported quarterly results View filing ↗
2025-07-08 Leadership change (directors/officers) View filing ↗
2025-06-18 Leadership change (directors/officers) (+1 more) View filing ↗
2025-05-01 Reported quarterly results View filing ↗
2025-02-13 Reported quarterly results View filing ↗

More Companies

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.